Published Date: 17-Mar-2020
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report LAMEA Contrast Media Market, published by KBV Research, the LAMEA Contrast Media Market would witness market growth of 4.55% CAGR during the forecast period (2019-2025).
The Brazil market dominated the LAMEA Gadolinium-based Market by Country in 2018, and would continue to be a dominant market till 2025. The Argentina market is anticipated to grow at a CAGR of 5% during (2019 - 2025). Additionally, The UAE market would witness a CAGR of 3.5% during (2019 - 2025).
The Neurological disorders market dominated the Saudi Arabia Contrast Media Market by Application in 2018, growing at a CAGR of 3.9 % during the forecast period. The Cancer market is expected to witness a CAGR of 5.3% during (2019 - 2025).
The X-ray/CT market dominated the South Africa Contrast Media Market by Modality in 2018thereby, achieving a market value of $37.7 million by 2025. The Ultrasound market is experiencing a market growth rate CAGR of 5.5% during (2019 - 2025).
Structural Insights: https://www.kbvresearch.com/lamea-contrast-media-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer AG, General Electric (GE) Co. (GE Healthcare), The Guerbet Group, Lantheus Holdings, Inc., Bracco S.p.A., Trivitron Healthcare Pvt. Ltd., Nano Therapeutics Pvt. Ltd., Magnus Health, LLC (Veracross LLC), Imax Diagnostic Imaging Limited, and Daiichi Sankyo Company, Limited.
By Product Type
Unique Offerings from KBV Research